Cytophage Technologies (TSXV:CYTO) Interest Expense : C$-0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cytophage Technologies's interest expense for the three months ended in Dec. 2023 was C$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cytophage Technologies's Operating Income for the three months ended in Dec. 2023 was C$ 3.20 Mil. Cytophage Technologies's Interest Expense for the three months ended in Dec. 2023 was C$ 0.00 Mil. Cytophage Technologies has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Cytophage Technologies Interest Expense Historical Data

The historical data trend for Cytophage Technologies's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Interest Expense Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Interest Expense

-0.03

-0.02

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Interest Expense	-	-0.01	-	-	-

Cytophage Technologies Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.00 Mil.

Cytophage Technologies (TSXV:CYTO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cytophage Technologies's Interest Expense for the three months ended in Dec. 2023 was C$0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was C$3.20 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was C$0.00 Mil.

Cytophage Technologies's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Cytophage Technologies had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Cytophage Technologies Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.